Second, our analysis only focused on the HER2-negative breast cancer, and previous studies demonstrated that the correlation between AR pathway activity and AR expression varied in HER2-positive and HER2-negative breast cancer [17,35]. Here, ERBB2 is linked to breast carcinoma.